Key Points
- Insider sale: David Kirn sold 58,333 shares of 4D Molecular Therapeutics at an average price of $13.90, totaling approximately $810,829 and reducing his position by 7.06%.
- Company performance: FDMT was trading at $13.76, up 1.0%, but reported a quarterly loss of $1.04 per share, slightly worse than analyst expectations. Analysts expect a full-year loss of approximately $4.07 per share.
- Investor outlook: Institutional investors own 99.27% of the company, while analysts maintain a “Moderate Buy” consensus with an average price target of $28.56, despite one sell rating.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider David Kirn sold 58,333 shares of the firm's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $13.90, for a total value of $810,828.70. Following the sale, the insider directly owned 767,486 shares in the company, valued at approximately $10,668,055.40. The trade was a 7.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Kirn also recently made the following trade(s):
- On Monday, August 3rd, David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75.
- On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
- On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
- On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62.
4D Molecular Therapeutics Stock Up 1.0%
NASDAQ:FDMT opened at $13.76 on Thursday. The company's 50-day simple moving average is $12.70 and its 200-day simple moving average is $10.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $16.93. The stock has a market capitalization of $760.10 million, a P/E ratio of -5.23 and a beta of 2.74.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.
Institutional Trading of 4D Molecular Therapeutics
Large investors have recently bought and sold shares of the stock. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics during the 2nd quarter valued at approximately $76,466,000. BlackRock Inc. acquired a new stake in shares of 4D Molecular Therapeutics during the second quarter worth $60,463,000. Janus Henderson Group PLC lifted its stake in shares of 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company's stock worth $48,868,000 after buying an additional 611,276 shares during the period. Trails Edge Capital Partners LP purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at $29,631,296. Finally, Bank of America Corp DE purchased a new stake in shares of 4D Molecular Therapeutics during the second quarter valued at $14,905,000. Hedge funds and other institutional investors own 99.27% of the company's stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a "buy" rating and set a $32.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. B. Riley Financial restated a "buy" rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $28.56.
Read Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Company Profile
(
Get Free Report)
4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.
Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
